ImmunityBio Reports First European Patients Treated With ANKTIVA Plus BCG
The first patients in Germany and Austria have been treated with ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
The first patients in Germany and Austria have been treated with ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.